Abstracts - faqs.org

Abstracts

Retail industry

Search abstracts:
Abstracts » Retail industry

US: ASTRAZENECA'S PRILOSEC DRUG SUFFERS SETBACK

Article Abstract:

AstraZeneca has suffered a setback for its drug Prilosec. US regulators questioned its suitability as an over-the-counter medicine. An advisory panel to the US Food and Drug Administration could not recommend Prilosec as an OTC heartburn drug until the long-term effects of using it were known. The drug might also mask gastric conditions preventing people seeking professional medical advice. AstraZeneca had been looking for OTC approval to extend the drug's sales life as it is about to come off patent in 2001. During 1999 Prilosec sold US$ 5.91bn in the US.

Publisher: Financial Times Ltd.
Publication Name: The Independent
Subject: Retail industry
ISSN: 0951-9467
Year: 2000
Antacid Preparations, Product development, AstraZeneca PLC, AZN, Antacids, Prilosec (Medication)

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


US: GLAXO WELLCOME RECEIVES APPROVAL FROM FDA

Article Abstract:

Glaxo Wellcome, the pharmaceutical group, has revealed that it has secured approval for its Trizivir triple combination tablet for the treatment of HIV from the US Food and Drug Administration (FDA). As a result of this approval the drug should be available in US pharmacies from December 2000.

Publisher: Financial Times Ltd.
Publication Name: The Independent
Subject: Retail industry
ISSN: 0951-9467
Year: 2000
Antiinfective Preparations, Laws, regulations and rules, Product information, Anti-infective agents, Glaxo Wellcome PLC, United States. Food and Drug Administration, Trizivir (Medication)

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


US: FDA EXTENDS FOSCAN REVIEW PERIOD

Article Abstract:

The US Food and Drug and Drug Administration (FDA) has decided to extend the review period of the Foscan cancer treatment developed by the UK pharmaceuticals company, Scotia Holdings. The review period will now continue from July to October 2000.

Publisher: Financial Times Ltd.
Publication Name: The Independent
Subject: Retail industry
ISSN: 0951-9467
Year: 2000
Anticancer Drugs, Standards, Antineoplastic agents, Scotia Holdings

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: United States, Pharmaceutical industry, Brief Article
Similar abstracts:
  • Abstracts: UK: TAKEOVER RUMOURS LIFT C&W. UK: NORWEB TELECOM APPOINTS NEW MD. UK: GROWING POPULARITY OF MOBILE PHONES
  • Abstracts: US: ANTI-MISSILE TECHNOLOGY TO BE SHARED. US: CLINTON PUTS MISSILE DEFENCE PROJECT ON HOLD
  • Abstracts: Eidos signs up Michael Owen UK: EMI DEFENDS HUGE MANAGEMENT PAYOUTS
  • Abstracts: UK: SCOTTISH SALMON FARMING MAY BE CURBED. The noble salmon: Wild. Mysterious. Prized above all other fish. And dying out in rivers all over Europe
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2026 Advameg, Inc.